Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$32.93
+0.4%
$28.02
$15.35
$36.44
$3.39B2.262.03 million shs1.79 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$9.38
-0.9%
$7.69
$5.37
$17.58
$612.38M1.771.16 million shs1.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$66.87
-3.1%
$54.17
$23.30
$71.04
$4.16B2.221.38 million shs2.13 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$46.34
-3.4%
$35.95
$22.61
$50.71
$3.70B1.89931,532 shs1.23 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+2.85%+18.54%+7.33%+15.25%+94.31%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+8.11%+17.54%+20.73%+41.94%+27.73%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+7.57%+17.34%+16.70%+47.12%+143.66%
Veracyte, Inc. stock logo
VCYT
Veracyte
+7.87%+6.20%+43.55%+31.16%+79.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$32.93
+0.4%
$28.02
$15.35
$36.44
$3.39B2.262.03 million shs1.79 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$9.38
-0.9%
$7.69
$5.37
$17.58
$612.38M1.771.16 million shs1.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$66.87
-3.1%
$54.17
$23.30
$71.04
$4.16B2.221.38 million shs2.13 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$46.34
-3.4%
$35.95
$22.61
$50.71
$3.70B1.89931,532 shs1.23 million shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
+2.85%+18.54%+7.33%+15.25%+94.31%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+8.11%+17.54%+20.73%+41.94%+27.73%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+7.57%+17.34%+16.70%+47.12%+143.66%
Veracyte, Inc. stock logo
VCYT
Veracyte
+7.87%+6.20%+43.55%+31.16%+79.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.71
Moderate Buy$46.8342.22% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.67
Reduce$8.50-9.33% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$58.00-13.26% Downside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.38
Hold$44.83-3.25% Downside

Current Analyst Ratings Breakdown

Latest TWST, BEAM, VCYT, and DNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Reiterated RatingBuy$48.00
5/22/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$80.00
5/21/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated RatingBuy$80.00
5/13/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Set Price Target$39.00
5/13/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Lower Price TargetOutperform$40.00 ➝ $39.00
5/6/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetBuy$48.00 ➝ $52.00
5/6/2026
Veracyte, Inc. stock logo
VCYT
Veracyte
Boost Price TargetHold$40.00 ➝ $42.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M24.24N/AN/A$11.32 per share2.91
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M3.60N/AN/A$6.78 per share1.38
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M11.06N/AN/A$7.31 per share9.15
Veracyte, Inc. stock logo
VCYT
Veracyte
$517.15M7.15$1.55 per share29.87$16.85 per share2.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.36N/AN/AN/A-215.41%-56.08%-26.06%8/6/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$66.35M$1.0942.5132.63N/A16.25%9.07%8.38%8/5/2026 (Estimated)

Latest TWST, BEAM, VCYT, and DNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million
5/5/2026Q1 2026
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.34$0.52+$0.18$0.35$130.36 million$139.07 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.09
16.99
16.99
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
5.15
5.15
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
9.31
8.92

Institutional Ownership

CompanyInstitutional Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
12.69%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510102.88 million98.97 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64065.32 million57.03 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79079.79 million78.68 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$32.93 +0.13 (+0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$32.52 -0.41 (-1.26%)
As of 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$9.38 -0.09 (-0.90%)
Closing price 03:59 PM Eastern
Extended Trading
$9.32 -0.05 (-0.59%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$66.87 -2.16 (-3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$66.94 +0.07 (+0.10%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$46.34 -1.65 (-3.44%)
Closing price 04:00 PM Eastern
Extended Trading
$46.62 +0.27 (+0.59%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.